A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
Status:
Unknown status
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label study of HMPL-689 administered orally to patients with lymphoma
for whom failed of standard care or have no standard of care.This study will consist of a
dose escalation stage (Stage I) and a dose expansion stage (Stage II).